Loading...
XLON
ONT
Market cap1.59bUSD
May 30, Last price  
123.40GBP
1D
0.08%
1Q
9.59%
IPO
-79.93%
Name

Oxford Nanopore Technologies PLC

Chart & Performance

D1W1MN
XLON:ONT chart
No data to show
P/E
P/S
646.98
EPS
Div Yield, %
Shrs. gr., 5y
2.47%
Rev. gr., 5y
28.61%
Revenues
183m
+7.97%
149,49100746,0004,529,00013,787,00032,521,00052,061,000113,860,000133,661,000198,603,000169,668,000183,191,000
Net income
-146m
L-5.38%
-19,159,495-24,215,000-36,973,000-38,511,000-59,101,000-56,536,000-53,119,000-72,216,000-61,244,000-167,613,000-91,025,000-154,507,000-146,188,000
CFO
-110m
L-19.97%
-21,274,143-23,270,000-33,876,000-33,137,999-51,207,000-66,345,000-55,509,000-48,679,000-63,806,000-53,826,000-49,387,000-137,302,000-109,885,000
Earnings
Jun 10, 2025

Profile

Oxford Nanopore Technologies plc develops and commercializes a technology platform using nanopore-based sensing for the analysis of various types of molecules. The company offers MinION, a portable device for deoxyribonucleic acid and ribonucleic acid sequencing; GridION, a self-contained benchtop device for running and analyzing up to five MinION or Flongle flow cells; MinION Mk1C for basecalling and data analysis, touchscreen operation, and wireless connectivity; Flongle, an adapter for use in MinION or GridION devices to attach a Flongle flow cell; GridION Mk1, a benchtop nanopore sequencer; PromethION 2 Solo and PromethION 2, a low-cost access to high-yield PromethION sequencing; PromethION 24 and PromethION 48 benchtop nanopore-based sequencers for multiple users to deliver multi-sample and multi-experiment sequencing results; and VolTRAX, an USB-powered device, which automates laboratory processes upstream of nanopore sequencing. It also provides MinKNOW, a software that offers data acquisition, real-time analysis and feedback, local basecalling, and data streaming; Basecalling tools to determine the identity and order of bases on the DNA/RNA molecule; EPI2ME, a cloud-based data analysis platform for end-to-end analysis of nanopore data in real time; and EPI2ME Labs, a bioinformatics solution to assist users in developing their skills and confidence in the analysis of their nanopore-based sequencing data. In addition, the company is developing MinION Mk1D; Ubi; Plongle; and SmidgION products. It sells its products online. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is based in Oxford, the United Kingdom.
IPO date
Sep 30, 2021
Employees
1,049
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
183,191
7.97%
169,668
-14.57%
198,603
48.59%
Cost of revenue
176,717
338,277
297,082
Unusual Expense (Income)
NOPBT
6,474
(168,609)
(98,479)
NOPBT Margin
3.53%
Operating Taxes
6,227
4,739
7,614
Tax Rate
96.18%
NOPAT
247
(173,348)
(106,093)
Net income
(146,188)
-5.38%
(154,507)
69.74%
(91,025)
-45.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
71,597
3,751
BB yield
-4.12%
-0.18%
Debt
Debt current
5,358
4,322
15,049
Long-term debt
86,570
78,988
53,147
Deferred revenue
(7,621)
Other long-term liabilities
3,616
6,679
8,753
Net debt
(320,756)
(395,807)
(373,552)
Cash flow
Cash from operating activities
(109,885)
(137,302)
(49,387)
CAPEX
(13,943)
(5,906)
(42,234)
Cash from investing activities
15,027
(61,794)
(65,794)
Cash from financing activities
73,581
64,734
(13,715)
FCF
2,643
(214,999)
(21,368)
Balance
Cash
338,370
270,050
476,189
Long term investments
74,314
209,067
(34,441)
Excess cash
403,524
470,634
431,818
Stockholders' equity
(193,359)
(54,702)
65,999
Invested Capital
829,277
746,887
658,563
ROIC
0.03%
ROCE
1.02%
EV
Common stock shares outstanding
897,796
833,960
823,743
Price
1.29
-38.14%
2.08
-15.54%
2.47
-64.68%
Market cap
1,156,362
-33.40%
1,736,305
-14.49%
2,030,526
-64.59%
EV
835,606
1,340,498
1,656,974
EBITDA
49,758
(126,982)
(66,608)
EV/EBITDA
16.79
Interest
2,206
1,628
Interest/NOPBT